加载中
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
前收盘价
US$2.09
+US$0.05 · +2.45%
盘后
US$2.10
+US$0.01 · +0.48%
10月16日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
日内区间
当前US$2.09
52周区间
当前US$2.09
盘中时间采用ET。市场数据可能有所延迟。
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
日内区间
当前US$2.09
52周区间
当前US$2.09
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 4748.2万 USD | 3.02亿 USD | 1668.54万 USD | 687.52万 USD | 434.08万 USD |
| 销货成本 | 326.25万 USD | 1374.58万 USD | 126.18万 USD | 88.18万 USD | 147.48万 USD |
| 毛利 | 4421.95万 USD | 2.88亿 USD | 1542.37万 USD | 599.34万 USD | 286.61万 USD |
| 研究与开发 | 708.61万 USD | 191.1万 USD | 34.2万 USD | 22.48万 USD | 11.96万 USD |
| 销售、一般及管理费用 | 3782.26万 USD | 2.55亿 USD | 2263.28万 USD | 1020.68万 USD | 418.79万 USD |
| 营业费用 | 4490.87万 USD | 2.57亿 USD | 2320.38万 USD | 1067.5万 USD | 447.18万 USD |
| 利息收入 | 41.38万 USD | — | — | — | — |
| 利息支出 | — | 58.72万 USD | 70.03万 USD | 46.82万 USD | 52.59万 USD |
| 折旧和摊销 | 38.1万 USD | 29.32万 USD | 22.9万 USD | 22.25万 USD | 28.38万 USD |
| 营业利润 | −68.91万 USD | 3120.06万 USD | −777.9万 USD | −468.15万 USD | −160.57万 USD |
| 净利润 | −658.09万 USD | 3188.43万 USD | −848.3万 USD | −719.29万 USD | −144.54万 USD |
公司数据更新于 2026年10月17日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$7.00
上涨空间 234.93%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2015年1月29日 | 1:400 | — | — |
股票拆分 | 2013年2月1日 | 1:35 | — | — |
股票拆分 | 2008年11月28日 | 1:1,000 | — | — |
已生效 2015年1月29日
1:400
已生效 2013年2月1日
1:35
已生效 2008年11月28日
1:1,000
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
